Cereno Scientific AB B CRNO B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 6.60
- Day Range
- SEK 6.74–7.33
- 52-Week Range
- SEK 2.50–7.44
- Bid/Ask
- SEK 7.20 / SEK 7.24
- Market Cap
- SEK 2.03 Bil
- Volume/Avg
- 1.7 Mil / 961,578
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.cerenoscientific.se
Comparables
Valuation
|
Metric
|
CRNO B
|
BIOA B
|
VICO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 59.90 | — |
Price/Book Value | 8.00 | 15.52 | 1.85 |
Price/Sales | — | 48.12 | 7.67 |
Price/Cash Flow | — | — | — |
Price/Earnings
CRNO B
BIOA B
VICO
Financial Strength
|
Metric
|
CRNO B
|
BIOA B
|
VICO
|
|---|---|---|---|
Quick Ratio | 2.66 | 3.41 | 11.98 |
Current Ratio | 2.66 | 7.18 | 11.98 |
Interest Coverage | −7.39 | — | — |
Quick Ratio
CRNO B
BIOA B
VICO
Profitability
|
Metric
|
CRNO B
|
BIOA B
|
VICO
|
|---|---|---|---|
Return on Assets (Normalized) | −24.89% | −7.63% | −40.50% |
Return on Equity (Normalized) | −30.08% | −8.67% | −44.50% |
Return on Invested Capital (Normalized) | −24.31% | −12.00% | −50.16% |
Return on Assets
CRNO B
BIOA B
VICO
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Dkrbfgsfx | Mwych | $88.3 Bil | |||
| Merck KGaA ADR
MKKGY
| Hfjkfbgx | Hfkjb | $77.4 Bil | |||
| Haleon PLC ADR
HLN
| Kdsqrsct | Crg | $47.3 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Yqfdnlxsz | Jyxrv | $19.0 Bil | |||
| Viatris Inc
VTRS
| Czksblvtx | Ctbrs | $13.9 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Jptxnhpx | Kbkq | $13.4 Bil | |||
| Catalent Inc
CTLT
| Xxzhmpcr | Yxhwcj | $10.9 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Fspkcbwq | Cqbwhm | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Kmhppmmg | Fttkz | $3.5 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Jqkgnklcqz | Rlfg | $2.5 Bil |
United States